A future direction combining more biomarkers, independently of type and origin, may be the most appropriate strategy in oncology, including HCC, showing that we still lack a score system accepted as the standard of care.15 Indeed, in our study, combining the GALAD score with the routinely used tests (albumin, bilirubin, and platelets) included in the ALBI and aMAP score did not improve the prediction of HCC development in any of the sub-cohort analyzed, further underlining the power of the pure GALAD system. The gene discussed is ALB; the disease is hepatocellular carcinoma.